Results 111 to 120 of about 260,075 (296)

Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution?

open access: yes, 2001
4th European Peritoneal Dialysis Meeting -- APR 15-18, 2000 -- MADRID, SPAINObjective: Peritoneal fibrosis (PF) is one of the most serious causes of failure in continuous ambulatory peritoneal dialysis (PD).
Fehmi Akçiçek   +15 more
core   +1 more source

Refining OVCAR‐3 xenograft models of peritoneal carcinomatosis in nu/nu mice: Comparative intraperitoneal implantation strategies and the role of basement membrane matrix

open access: yesAnimal Models and Experimental Medicine, EarlyView.
A refined murine model of advanced ovarian cancer was established by comparing localized preperitoneal implantation and intraperitoneal injection of OVCAR‐3Luc cells. While localized implantation showed limited tumor persistence, intraperitoneal delivery with BME produced sustained diffuse dissemination confirmed by BLI and histology, providing a ...
M. Teresa Perelló‐Trias   +5 more
wiley   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

open access: yesAngewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber   +4 more
wiley   +1 more source

TECHNICAL ASPECTS IN STUDYING PERITONEAL MORPHOLOGY IN ANIMAL MODELS OF PERITONEAL DIALYSIS

open access: yes, 2009
12th Congress of the International-Society-for-Peritoneal-Dialysis -- JUN 20-24, 2008 -- Istanbul, TURKEYObjective: Peritoneal biopsies are considered useful for gaining a better understanding of the pathophysiology of the peritoneum during experimental ...
Sen, Sait, Duman, Soner
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

High-Grade and Low-Grade Pelvic Serous Neoplasms Demonstrate Differential p53 Immunoreactivity in Peritoneal Washings

open access: yes, 2010
<i>Objective:</i> Serous neoplasms of the female pelvis share a müllerian phenotype. Unlike low-grade serous neoplasms (LGSNs), high-grade serous carcinomas (HGSCs) commonly display p53 mutations.
Christopher P. Crum   +3 more
core   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

Paradoxes in peritoneal transport of small solutes

open access: yes, 1996
Analysis of kinetic studies of peritoneal solute transport involves the need for discrimination between three transport components: diffusion, convective transport, and peritoneal absorption.
Heimbürger, O   +3 more
core  

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy